Table 2.
Lists of all-types of CVAE, major CVAEs and hypertension-related CVAEs.
| CVAE | Patients n = 116 No. (%) * |
No. CVAEs | |
|---|---|---|---|
| Grade 1–2 | Grade ≥3 | ||
| Major CVAEs | 17 (14.7) | 12 | 10 |
| ACS (STEMI) | 1 (0.9) | 0 | 1 |
| ACS (NSTEMI) | 3 (2.6) | 0 | 3 |
| Typical Chest pain | 3 (2.6) | 3 | 0 |
| Heart failure | 1 (0.9) | 0 | 1 |
| Dyspnoea post infusion | 4 (3.5) | 2 | 2 |
| Syncope/pre-syncope | 1 (0.9) | 0 | 1 |
| Arrhythmias | 7 (6.0) | 6 | 1 |
| Sudden cardiac death | 1 (0.9) | NA | 1 |
| Hypertension-related CVAEs | 45 (38.7) | 75 | 29 |
| New onset/worsened hypertension | 37 (31.9) | 37 | 0 |
| Masked hypertension | 4 (3.5) | 4 | 0 |
| White coat hypertension | 0 (0) | 0 | 0 |
| Pre-infusion uncontrolled hypertension [infusion limiting] |
11 (9.5) | 6 | 9 |
| Pre-infusion uncontrolled hypertension [not-infusion limiting] |
20 (17.2) | 20 | 10 |
| Post-infusion uncontrolled hypertension | 11 (9.5) | 8 | 6 |
| Symptomatic uncontrolled hypertension | 4 (3.5) | 0 | 4 |
| Hypertensive emergency | 0 (0) | 0 | 0 |
| All-type CVAEs | 52 (44.9) | 87 | 39 |
| Both major and hypertensive CVAEs | 10 (8.6) | 26 | 13 |
* patients experienced more than one CVAE, hence total % amount to > 100. CVAEs = cardiovascular adverse events; ACS = acute coronary syndrome; STEMI = ST-elevation myocardium infarction; NSTEMI = Non-ST-elevation myocardial infarction.